GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Concert Pharmaceuticals Inc (NAS:CNCE) » Definitions » Equity-to-Asset

Concert Pharmaceuticals (Concert Pharmaceuticals) Equity-to-Asset : 0.78 (As of Sep. 2022)


View and export this data going back to 2014. Start your Free Trial

What is Concert Pharmaceuticals Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Concert Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Sep. 2022 was $133.27 Mil. Concert Pharmaceuticals's Total Assets for the quarter that ended in Sep. 2022 was $171.13 Mil. Therefore, Concert Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Sep. 2022 was 0.78.

The historical rank and industry rank for Concert Pharmaceuticals's Equity-to-Asset or its related term are showing as below:

CNCE' s Equity-to-Asset Range Over the Past 10 Years
Min: -3.22   Med: 0.82   Max: 0.93
Current: 0.78

During the past 11 years, the highest Equity to Asset Ratio of Concert Pharmaceuticals was 0.93. The lowest was -3.22. And the median was 0.82.

CNCE's Equity-to-Asset is not ranked
in the Biotechnology industry.
Industry Median: 0.66 vs CNCE: 0.78

Concert Pharmaceuticals Equity-to-Asset Historical Data

The historical data trend for Concert Pharmaceuticals's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Concert Pharmaceuticals Equity-to-Asset Chart

Concert Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.93 0.87 0.74 0.82 0.68

Concert Pharmaceuticals Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.77 0.68 0.59 0.72 0.78

Competitive Comparison of Concert Pharmaceuticals's Equity-to-Asset

For the Biotechnology subindustry, Concert Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Concert Pharmaceuticals's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Concert Pharmaceuticals's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Concert Pharmaceuticals's Equity-to-Asset falls into.



Concert Pharmaceuticals Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Concert Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Equity to Asset (A: Dec. 2021 )=Total Stockholders Equity/Total Assets
=112.225/165.316
=0.68

Concert Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Sep. 2022 is calculated as

Equity to Asset (Q: Sep. 2022 )=Total Stockholders Equity/Total Assets
=133.272/171.134
=0.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Concert Pharmaceuticals  (NAS:CNCE) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Concert Pharmaceuticals Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Concert Pharmaceuticals's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Concert Pharmaceuticals (Concert Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
65 Hayden Avenue, Suite 3000N, Lexington, MA, USA, 02421
Concert Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company aims to discover and develop small-molecule drugs by incorporating new elements into known molecules or by leveraging the currently approved drugs to be used for new treatments. The pipeline consists of small molecules designed for oral administration to cure cystic fibrosis, inflammation, narcolepsy, residual schizophrenia, major depressive disorder, and Alzheimer's agitation.
Executives
James V Cassella officer: Chief Development Officer 2091 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Marc A. Becker officer: CFO, PFO 175 CROSSING BLVD., 4TH FLOOR, FRAMINGHAM MA 01702
Nancy Stuart officer: Chief Operating Officer 99 HAYDEN AVENUE, SUITE 500, LEXINGTON MA 02421
Jeffrey A Munsie officer: Chief Legal Officer CONCERT PHARMACEUTICALS, INC., 65 HAYDEN AVENUE, SUITE 3000N, LEXINGTON MA 02421
Roger D Tung director, officer: Chief Executive Officer 99 HAYDEN AVENUE, SUITE 500, LEXINGTON MA 02421
Peter Barton Hutt director
Thomas G Auchincloss director C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Richard Aldrich director 1365 MAIN STREET, WALTHAM MA 02451
Heek Christi Van director 4001 MIRANDA AVENUE, PALO ALTO CA 94304
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Jesper Hoeiland director C/O RADIUS HEALTH, INC., 950 WINTER STREET, WALTHAM MA 02451
Ronald W Barrett director C/O XENOPORT, INC., 3410 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051
Wendall Wierenga director 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Wilfred E Jaeger director C/O THREE ARCH PARTNERS, 3200 ALPINE RD, PORTOLA VALLEY CA 94028
Meghan Fitzgerald director C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511

Concert Pharmaceuticals (Concert Pharmaceuticals) Headlines

From GuruFocus